Office of Akero Therapeutics Catriona Yale disclosed in a filing that she had sold 5,000 shares of company stock at on January 13 at $50.53 per share, for a total transaction amount of $252,651.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AKRO:
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Akero Therapeutics appoints Patrick Lamy as SVP, commercial strategyIovance Biotherapeutics
- Akero completes enrollment in Phase 2b efruxifermin study for treatment of NASH
- Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
- Madrigal Pharmaceuticals price target raised to $325 from $175 at Evercore ISI